Plasma protein binding was assessed using ultrafiltration.
Watanabe, T. A., Geary, R. S. & Levin, A. A. Plasma protein binding of an antisense oligonucleotide targeting human ICAM-1 (ISIS 2302).
BAY 2402234 has moderate plasma protein binding (fu = 9.9%), low blood clearance (CLb = 0.87 L/h/kg) and a high volume of distribution Vss = 3.0 L/kg.
The method has been validated using literature plasma protein binding data of 68 known drug molecules.
Therefore, this method can be applied to determine the plasma protein binding in clinical practice.
Human plasma protein binding was similar for NTBI, DEI, and des-ethyl amodiaquine (DEA).
For risperidone, plasma protein binding varied from 67to43%3% and cardiac homogenate binding varied from 90 to 78%.
The plasma protein binding ratio of 1b was lower than that of Pactimibe: 64.8% and 97.9%, respectively.
In accordance, the conjugate was cleared much faster from the blood stream, due to a significant lower plasma protein binding.
The aim of our study was to calculate the contribution of the plasma protein binding (PPB) to this shift.
Plasma protein binding (PPB) strongly affects drug distribution and pharmacokinetic behavior with consequences in overall pharmacological action.
